Malcolm Brenner,Gianpietro Dotti,Nabil M. Ahmed,Claudia Rossig,Stephen M. G. Gottschalk,Zakaria Grada
申请号：
US15293011
公开号：
US20170027988A1
申请日:
2016.10.13
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).
